Cost-effectiveness of PCSK9 Inhibitors for Heterozygous FH or ASCVD

Interview with Dhruv S. Kazi, MD, MSc, MS, author of Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease

Source: JAMA Author Interviews - August 16, 2016 Category: Journals (General) Authors: JAMA, the Journal of the American Medical Association, and The JAMA Network Source Type: podcasts